| Title: |
Valomindo - metabolički neutralna kombinacija sartana i diuretika. |
| Alternate Title: |
Valomindo - a metabolically neutral combination of a sartan and a diuretic. |
| Authors: |
Lovrić, Daniel1 daniel@dlovric.net |
| Source: |
Cardiologia Croatica. Jan/Feb2025, Vol. 20 Issue 1/2, p49-53. 5p. |
| Subject Terms: |
*PATIENT compliance, *VENTRICULAR remodeling, *BLOOD pressure, *RENIN-angiotensin system, *INDAPAMIDE |
| Abstract (English): |
Arterial hypertension is one of the leading causes of cardiovascular (CV) morbidity and mortality worldwide, with a significant proportion of patients failing to achieve target blood pressure (BP) values. The combination of valsartan and indapamide represents a modern therapeutic approach, combining the benefits of renin-angiotensin system inhibition with the antihypertensive effects of a thiazide-like diuretic that has a favorable metabolic profile. Valsartan is distinguished by its efficacy, tolerability, and beneficial effects on renal and CV function, while indapamide surpasses hydrochlorothiazide in BP control, left ventricular remodeling, and CV outcomes. The fixed combination of these drugs, particularly in a slow-release formulation and with the possibility of evening dosing, further enhances patient adherence and optimal hypertension management, thereby reducing overall CV risk. European hypertension treatment guidelines recommend such drug combinations due to their effectiveness and safety profile, enabling a personalized approach to hypertension management. [ABSTRACT FROM AUTHOR] |
| Abstract (Croatian): |
Arterijska hipertenzija jedan je od vodećih uzroka kardiovaskularnog (KV) morbiditeta i mortaliteta u svijetu, uz znatan broj bolesnika u kojih ciljne vrijednosti arterijskoga tlaka (AT) ostaju nepostignute. Kombinacija valsartana i indapamida suvremeni je terapijski pristup koji sjedinjuje prednosti inhibicije renin-angiotenzinskog sustava i antihipertenzivnog djelovanja tiazidima sličnog diuretika s povoljnim metaboličkim profilom. Valsartan se ističe učinkovitošću, podnošljivošću i povoljnim učincima na bubrežnu i KV funkciju, dok indapamid nadmašuje hidroklorotiazid u kontroli AT-a, remodelaciji lijeve klijetke te KV ishodima. Fiksna kombinacija ovih lijekova, posebno u slow release formulaciji i uz moguće i večernje doziranje, dodatno pridonosi adherenciji bolesnika i optimalnoj kontroli hipertenzije, čime se smanjuje ukupan KV rizik. Europske smjernice za liječenje hipertenzije preporučuju ovakve kombinacije lijekova zbog njihove učinkovitosti i sigurnosnog profila, čime se omogućuje individualizirani pristup liječenju hipertenzije. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cardiologia Croatica is the property of Croatian Cardiac Society and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
